A California-based biotech company says it has successfully implanted lab-made neurons in Parkinsons patients' brains to simulate a dopamine response — and if it works as intended, it'll be a huge advent for the disease. As the MIT Technology Review reports, the early stem cell experiment, which was meant to see if the procedure is safe […]
A Bayer cell therapy for Parkinson’s disease has met primary and secondary goals of its first test in humans, and the pharmaceutical giant is now planning for a larger Phase 2 clinical trial expected to begin enrollment in the first half of next year.
Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose.